Effect Of Rosiglitazone On The Treatment Of Polycystic Ovary Syndrome-the Clinical Analysis Of Five Cases

[Objective] To evaluate the effect of rosiglitazone on endocrine, metabolism and ovulation in women with polycystic ovary syndrome (PCOS) and insulin resistance.[Methods] Five patients with PCOS plus insulin resistance were treated with rosiglitazone for 12 weeks. Before and after the treatment, serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E₂), testosterone (T), insulin and glucose, HOMA-IR, total cholesterol, triglycerides (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A and apolipoprotein B, as well as ovulation induction were determined.[Results] After the treatment, serum levels of insulin, HOMA-IR decreased significantly (P<0.01) ; HDL-C inceased (P<0.05) while LDL-C decreased (P> 0.05) ; LH , T, A and LH/FSH ratio decreased (P<0.05) . During the treatment, menstrual disorders and ovulation of the patients turned to regularity. And one patient succeeded to become pregnant.[ Conclusion ] The reduction of hyerinsulinemia by rosiglitazone may effectively improve the endocrine, metabolism and ovulatory performance in women with PCOS and insulin resistance.